AZN - AstraZeneca PLC

NYSE - Nasdaq Real-time price. Currency in USD
34.96
-0.10 (-0.29%)
As of 11:34AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close35.06
Open35.26
Bid34.95 x 3200
Ask34.96 x 800
Day's range34.92 - 35.31
52-week range28.43 - 37.30
Volume1,460,863
Avg. volume3,897,761
Market cap88.675B
Beta0.58
PE ratio (TTM)31.58
EPS (TTM)1.11
Earnings dateN/A
Forward dividend & yield1.40 (3.99%)
Ex-dividend date2018-02-15
1y target est39.09
Trade prices are not sourced from all markets
  • Business Wire4 hours ago

    FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits Vs. Insulin Glargine in Patients with Type 2 Diabetes

    AstraZeneca presented key data on the use of FARXIGA® in diverse patient populations with type 2 and type 1 diabetes at the American Diabetes Association 78th Scientific Sessions this week in Orlando, FL, June 22-26, 2018.

  • Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines
    Motley Foolyesterday

    Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines

    These drugmakers arguably have the strongest pipelines. But are they all great stocks to buy?

  • Lynparza Could Be Merck’s Long-Term Growth Driver
    Market Realist5 days ago

    Lynparza Could Be Merck’s Long-Term Growth Driver

    Merck & Company (MRK) and AstraZeneca (AZN) jointly develop and commercialize Lynparza. In June, Merck and AstraZeneca presented data from the Study 08 trial, in which a combination of Lynparza and abiraterone demonstrated an improvement in median radiologic progression-free survival (or rPFS) compared to abiraterone monotherapy.

  • Business Wire6 days ago

    AstraZeneca to Share Latest Data from an Industry-Leading Portfolio That Aims to Advance Clinical Understanding of Diabetes and CV Risk Management at ADA 2018

    AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company’s Cardiovascular , Renal and Metabolism therapy area at the American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida, June 22-26, 2018.

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks10 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • The Wall Street Journal13 days ago

    [$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials

    AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.

  • AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap
    Investor's Business Daily13 days ago

    AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap

    AstraZeneca and Eli Lilly became the latest Tuesday in a series of firms to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.

  • Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
    Zacks13 days ago

    Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

    Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

  • Alzheimer's Research Stumbles Again: What's the Road Ahead?
    Zacks13 days ago

    Alzheimer's Research Stumbles Again: What's the Road Ahead?

    The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

  • Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests
    Bloomberg13 days ago

    Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests

    Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness. An independent data monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.

  • AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer
    Zacks14 days ago

    AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

    AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

  • What’s in AstraZeneca’s Research Pipeline for Fiscal 2019
    Market Realist14 days ago

    What’s in AstraZeneca’s Research Pipeline for Fiscal 2019

    In the second half of fiscal 2018, major news is expected for indications in diabetes, anemia, COPD (chronic obstructive pulmonary disease), and lupus in AstraZeneca’s (AZN) pipeline. A data readout is expected from the DECLARE trial for Farxiga for type 2 diabetes, and a regulatory decision in the European Union is expected for the Bydureon autoinjector for type 2 diabetes.

  • A Look At AstraZeneca’s Research Pipeline
    Market Realist14 days ago

    A Look At AstraZeneca’s Research Pipeline

    Investors have a lot to watch for in AstraZeneca’s (AZN) research pipeline in the second fiscal quarter. The company expects a data readout for Lynparza in an ovarian cancer indication. A regulatory decision is expected for Tagrisso in the European Union for lung cancer.

  • Analyzing AstraZeneca’s Cash Flow and Valuation
    Market Realist14 days ago

    Analyzing AstraZeneca’s Cash Flow and Valuation

    In the first quarter, AstraZeneca’s (AZN) cash outflow from operating activities rose YoY (year-over-year) to $140 million from $88 million, due to an increase in the movement of working capital and higher short-term provisions for the launch of new medicines. AstraZeneca generated $273 million from investing activities in the first quarter, compared with $146 million in Q1 2017. This change was due to lower capital expenditure and the timing of receipts on disposal of intangible assets.

  • What to Expect for AstraZeneca in Fiscal 2018
    Market Realist17 days ago

    What to Expect for AstraZeneca in Fiscal 2018

    AstraZeneca (AZN) has maintained its guidance for fiscal 2018. This expected growth in product sales is weighted towards the second half of the year, reflecting the impact of generic competition for Crestor in Europe and Japan and an increased revenue contribution from new medicines. AstraZeneca expects the sum of externalization revenue and other operating income and expenses to fall YoY (year-over-year).

  • How AstraZeneca Performed in the First Quarter
    Market Realist17 days ago

    How AstraZeneca Performed in the First Quarter

    In the first quarter, AstraZeneca’s (AZN) sales were boosted by strong product launches and newer medicines and partially offset by a decrease in Crestor sales. AstraZeneca’s total revenue fell 4% YoY (year-over-year) to $5.2 billion in Q1 2018. AstraZeneca expects to return to growth in fiscal 2018.

  • Analysts’ Recommendations for AstraZeneca and Peers
    Market Realist17 days ago

    Analysts’ Recommendations for AstraZeneca and Peers

    Investors have a lot to watch for when it comes to AstraZeneca (AZN) stock, with key events expected in the company’s research pipeline and higher uptake expected for the company’s new medicines on the market. In this series, we’ll explore what analysts think of AstraZeneca’s stock potential, financial performance, valuation, and more. Of the six analysts covering AstraZeneca, four have recommended “buy” or a higher rating, while two have recommended “hold.” Their mean rating for the stock is 1.8, and their target price is $39.09.

  • Business Wire21 days ago

    LYNPARZA® (olaparib) in Combination With Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer

    AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data, which showed clinical improvement in median radiologic progression-free survival with LYNPARZA®  in combination with abiraterone compared to abiraterone monotherapy, a current standard of care, in metastatic castration-resistant prostate cancer .

  • Analysts Give Mixed Recommendations for Novartis
    Market Realist21 days ago

    Analysts Give Mixed Recommendations for Novartis

    As discussed earlier, Novartis (NVS) reported EPS of $1.28 and revenue of $12.7 billion in the first quarter. In the second quarter, its revenue is expected to rise 7.8% year-over-year to $13.2 billion from $12.2 billion. The chart below shows analysts’ recommendations for Novartis over the last 12 months.

  • 3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
    Zacks21 days ago

    3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

    Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.

  • Key Developments for Novartis in the Past Month
    Market Realist21 days ago

    Key Developments for Novartis in the Past Month

    As discussed earlier, Novartis’s (NVS) operating revenue grew 4% year-over-year in the first quarter, to ~$12.7 billion from ~$11.5 billion. The chart below shows recent developments for Novartis. On May 30, the FDA accepted Novartis’s supplemental new drug application for the drug Promacta, and granted priority review designation to Promacta in combination with standard immunosuppressive therapy as a first-line treatment for severe aplastic anemia.

  • Business Wire23 days ago

    Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting

    AstraZeneca and MedImmune, its global biologics research and development arm, today presented results from the Phase III clinical trial that evaluated mox

  • How Does AstraZeneca PLC (LON:AZN) Fare As A Dividend Stock?
    Simply Wall St.24 days ago

    How Does AstraZeneca PLC (LON:AZN) Fare As A Dividend Stock?

    A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Over the past 10 years, AstraZeneca PLCRead More...

  • How Novartis’s Sandoz Business Performed in Q1
    Market Realist24 days ago

    How Novartis’s Sandoz Business Performed in Q1

    Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics—products that are difficult to develop and manufacture. Sandoz revenue grew 4% YoY (year-over-year) to ~$2.5 billion in the first quarter. The chart below shows Sandoz’s revenue since Q1 2017.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes